Literature DB >> 18757437

Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma.

Valentina Fogal1, Lianglin Zhang, Stan Krajewski, Erkki Ruoslahti.   

Abstract

A tumor homing peptide, LyP-1, selectively binds to tumor-associated lymphatic vessels and tumor cells in certain tumors and exhibits an antitumor effect. Here, we show that the protein known as p32 or gC1q receptor is the receptor for LyP-1. Various human tumor cell lines were positive for p32 expression in culture, and the expression was increased in xenograft tumors grown from the positive cell lines. Fluorescence-activated cell sorting analyses with anti-p32 antibodies showed that p32-positive cell lines expressed p32 at the cell surface. These cells bound and internalized LyP-1 peptide in proportion to the cell-surface expression level, which correlated with malignancy rather than total p32 expression in the cells. Like the LyP-1 peptide, p32 antibodies highlighted hypoxic areas in tumors, where they bound to both tumor cells and cells that expressed macrophage/myeloid cell markers and often seemed to be incorporated into the walls of tumor lymphatics. Significant p32 expression was common in human cancers and the p32 levels were often greatly elevated compared with the corresponding normal tissue. These results establish p32, particularly its cell-surface-expressed form, as a new marker of tumor cells and tumor-associated macrophages/myeloid cells in hypoxic/metabolically deprived areas of tumors. Its unique localization in tumors and its relative tumor specificity may make p32 a useful target in tumor diagnosis and therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18757437      PMCID: PMC2562323          DOI: 10.1158/0008-5472.CAN-07-6752

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  Up-regulation of endothelial cell binding proteins/receptors for complement component C1q by inflammatory cytokines.

Authors:  W X Guo; B Ghebrehiwet; B Weksler; K Schweitzer; E I Peerschke
Journal:  J Lab Clin Med       Date:  1999-06

2.  Lymphangiogenesis and cancer: meeting report.

Authors:  Kari Alitalo; Suresh Mohla; Erkki Ruoslahti
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

3.  Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages.

Authors:  Kazuichi Maruyama; Masaaki Ii; Claus Cursiefen; David G Jackson; Hiroshi Keino; Minoru Tomita; Nico Van Rooijen; Hideya Takenaka; Patricia A D'Amore; Joan Stein-Streilein; Douglas W Losordo; J Wayne Streilein
Journal:  J Clin Invest       Date:  2005-09       Impact factor: 14.808

4.  Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants.

Authors:  Dontscho Kerjaschki; Nicole Huttary; Ingrid Raab; Heinz Regele; Katalin Bojarski-Nagy; Gregor Bartel; Stefan M Kröber; Hildegard Greinix; Agathe Rosenmaier; Franz Karlhofer; Nikolaus Wick; Peter R Mazal
Journal:  Nat Med       Date:  2006-01-15       Impact factor: 53.440

5.  Biomimetic amplification of nanoparticle homing to tumors.

Authors:  Dmitri Simberg; Tasmia Duza; Ji Ho Park; Markus Essler; Jan Pilch; Lianglin Zhang; Austin M Derfus; Meng Yang; Robert M Hoffman; Sangeeta Bhatia; Michael J Sailor; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-10       Impact factor: 11.205

6.  Crystal structure of human p32, a doughnut-shaped acidic mitochondrial matrix protein.

Authors:  J Jiang; Y Zhang; A R Krainer; R M Xu
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

7.  The crucial role of macrophages in lymphangiogenesis.

Authors:  Dontscho Kerjaschki
Journal:  J Clin Invest       Date:  2005-09       Impact factor: 14.808

8.  Differential expression of Hyaluronic Acid Binding Protein 1 (HABP1)/P32/C1QBP during progression of epidermal carcinoma.

Authors:  Ilora Ghosh; Anindya Roy Chowdhury; Moganty R Rajeswari; Kasturi Datta
Journal:  Mol Cell Biochem       Date:  2004-12       Impact factor: 3.396

9.  Lymphatic zip codes in premalignant lesions and tumors.

Authors:  Lianglin Zhang; Enrico Giraudo; Jason A Hoffman; Douglas Hanahan; Erkki Ruoslahti
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

Review 10.  Chemotherapy targeted to tumor vasculature.

Authors:  W Arap; R Pasqualini; E Ruoslahti
Journal:  Curr Opin Oncol       Date:  1998-11       Impact factor: 3.645

View more
  128 in total

1.  Coadministration of a tumor-penetrating peptide improves the therapeutic efficacy of paclitaxel in a novel air-grown lung cancer 3D spheroid model.

Authors:  Sweta K Gupta; Elisa A Torrico Guzmán; Samantha A Meenach
Journal:  Int J Cancer       Date:  2017-08-18       Impact factor: 7.396

2.  Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.

Authors:  Carlos M Galmarini; Galya Warren; Madapathage T Senanayake; Serguei V Vinogradov
Journal:  Int J Pharm       Date:  2010-05-24       Impact factor: 5.875

3.  Design of Nanoparticle-Based Carriers for Targeted Drug Delivery.

Authors:  Xiaojiao Yu; Ian Trase; Muqing Ren; Kayla Duval; Xing Guo; Zi Chen
Journal:  J Nanomater       Date:  2016       Impact factor: 2.986

Review 4.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

5.  Elevated expression of HABP1 is correlated with metastasis and poor survival in breast cancer patients.

Authors:  Ming Niu; Shanshan Sun; Guoqiang Zhang; Yashuang Zhao; Da Pang; Yanbo Chen
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

6.  Cell-surface receptor for complement component C1q (gC1qR) is a key regulator for lamellipodia formation and cancer metastasis.

Authors:  Ki-Bum Kim; Jae-Sung Yi; Nga Nguyen; Joo-Hyung Lee; Young-Chan Kwon; Byung-Yoon Ahn; Hana Cho; Yoon Ki Kim; Hee-Jung Yoo; Jae-Seon Lee; Young-Gyu Ko
Journal:  J Biol Chem       Date:  2011-05-02       Impact factor: 5.157

7.  Interactions between RNA-binding proteins and P32 homologues in trypanosomes and human cells.

Authors:  Juan Manuel Polledo; Gabriela Cervini; María Albertina Romaniuk; Alejandro Cassola
Journal:  Curr Genet       Date:  2015-09-18       Impact factor: 3.886

8.  Cooperative nanomaterial system to sensitize, target, and treat tumors.

Authors:  Ji-Ho Park; Geoffrey von Maltzahn; Mary Jue Xu; Valentina Fogal; Venkata Ramana Kotamraju; Erkki Ruoslahti; Sangeeta N Bhatia; Michael J Sailor
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

9.  Tissue-penetrating delivery of compounds and nanoparticles into tumors.

Authors:  Kazuki N Sugahara; Tambet Teesalu; Priya Prakash Karmali; Venkata Ramana Kotamraju; Lilach Agemy; Olivier M Girard; Douglas Hanahan; Robert F Mattrey; Erkki Ruoslahti
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

10.  Targeting of albumin-embedded paclitaxel nanoparticles to tumors.

Authors:  Priya Prakash Karmali; Venkata Ramana Kotamraju; Mark Kastantin; Matthew Black; Dimitris Missirlis; Matthew Tirrell; Erkki Ruoslahti
Journal:  Nanomedicine       Date:  2008-10-01       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.